The goal of this clinical trial is to test the analgesic efficacy of rhomboid intercostal nerve block (RINB) in patients undergoing minimal invasive heart surgery (MIHS). The main questions it aims to answer are: * How will the total perioperative opioid consumption of the patients receiving RINB change? * How will RINB effect the patients' numeric rating scores for pain in the postoperative 24-hour period? * How will RINB effect the postoperative extubation times? * How will RINB effect the length of intensive care unit (ICU) stays on the postoperative period? * How will RINB effect the incidence of opioid related side effects? Participants will be divided in two groups: * Block group will receive a RINB before the surgery. * Control group will not receive any nerve block. Researchers will compare the results between the groups to see the postoperative effects concerning opioid consumption as well as the pain scores, respiratory parameters and ICU length of stay of the patients receiving RINB for minimal invasive heart surgery. The hypothesis of this study is that participants receiving RINB for MIHS will have a less total opioid consumption 24 hours postoperatively.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Total opioid consumption
Timeframe: 24 hours post-surgery